Allergy Treatment Market by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, and Others), Treatment (Anti-Allergy Drugs and Immunotherapy), Dosage Form (Oral, Inhalers, Intranasal, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Retailers, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3248
- Pages: 220
-
Format:
Allergy Treatment Market Overview :
The global allergy treatment market was valued at $24,653 million in 2017, and is expected to reach $40,360 million by 2025, registering a CAGR of 6.3% from 2018 to 2025.
Allergy is a major health concern across the globe. An allergic reaction is a hypersensitive response of the immune system to the allergens present in the environment. Substances or allergens, which are more potent to cause an allergic reaction include mold, grass, pollen grains, peanut, egg, soy, and others. In addition, according to the WHO, by 2050, 1 in 2 people are expected to suffer from allergies. Further, the American Academy of Allergy Asthma and Immunology concluded that the rise in prevalence of allergies in the industrialized world is estimated to continue for more than 50 years worldwide. This is predicted to boost the growth of the allergy treatment market.
Rise in preference toward over-the-counter drugs for allergy treatment and surge in self-medication by consumers are the major factors that drive the market growth. In addition, innovative developments in the field of allergy immunotherapy (AIT) such as advent of sub-lingual, allergen specific immunotherapy, further accelerate the growth of the global allergy treatment market. However, increased preference toward the use of biosimilars to treat allergies and safety & efficacy concerns regarding the side effects of anti-allergy drugs are anticipated to hamper the growth of the allergy treatment market. On the contrary, increased R&D investments by the manufacturers toward the development of novel anti-allergy treatment medications is expected to create lucrative opportunities in future.
The global allergy treatment market is segmented based on type, treatment, dosage form, and distribution channels. Based on type, the market is divided into eye allergy, skin allergy, food allergy, rhinitis, asthma, and others. Based on treatment, the market is bifurcated into anti-allergy drugs and immunotherapy. Based on dosage form, it is classified into oral, intranasal, inhalers, and others. Based on distribution channel, it is classified into hospital pharmacies, retail pharmacies, online retailers, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Allergy Treatment Market :
The study provides an in-depth analysis of the global allergy treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps understand the global trends in the allergy treatment market.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Allergy Treatment Key Market Segments :
By Type
Eye Allergy
Skin Allergy
Food Allergy
Rhinitis
Asthma
Others
By Treatment
Anti-Allergy Drugs
Immunotherapy
By Dosage Form
Oral
Intranasal
Inhalers
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Retailers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
South Africa
Brazil
Turkey
Rest of LAMEA
Key Market Players
Merck KGaA (Allergopharma)
GlaxoSmithKline
Allergy Therapeutics
F. Hoffmann-La Roche AG
Merck Co. & Inc.
ALK-Abell A/S
Sallergenes Greer
Allergan plc
Sanofi SA
Johnson & Johnson
The other players in the value chain include (profiles not included in the report)
NOVARTIS AG
Sunovion Pharmaceuticals Inc
HAL Allergy Group
Collegium Pharmaceutical, Inc.
Procter & Gamble
Circassia
Mylan NV
Teva Pharmaceuticals
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. The rising importance for self-medication
3.5.1.2. Increase in incidence of food allergies across the globe
3.5.1.3. Increased investment by the manufacturers on the development of novel allergic treatments
3.5.2. Restraints
3.5.2.1. Rise in preference towards the use of biosimilars
3.5.2.2. Low awareness of allergy immunotherapy (AIT) among patients
3.5.3. Opportunity
3.5.3.1. Innovative developments in the field of immunotherapy
CHAPTER 4: ALLERGY TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Eye allergy
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Rhinitis
4.3.1. Key trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Asthma
4.4.1. Key trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Skin Allergy
4.5.1. Key trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Food Allergies
4.6.1. Key trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Other Allergies
4.7.1. Key trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
CHAPTER 5: ALLERGY TREATMENT MARKET, BY TREATMENT
5.1. Overview
5.1.1. Market size and forecast
5.2. Anti-Allergy Drugs
5.2.1. Market size and forecast
5.2.2. Antihistamines
5.2.2.1. Market size and forecast
5.2.3. Corticosteroids
5.2.3.1. Market size and forecast
5.2.4. Decongestants
5.2.4.1. Market size and forecast
5.2.5. Other Drugs
5.2.5.1. Market size and forecast
5.3. Immunotherapy
5.3.1. Market size and forecast
5.3.2. Subcutaneous Immunotherapy (SCIT)
5.3.2.1. Market size and forecast
5.3.3. Sun-Lingual Immunotherapy (SLIT)
5.3.3.1. Market size and forecast
CHAPTER 6: ALLERGY TREATMENT MARKET, BY DOSAGE FORM
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Inhalers
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Intranasal
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
6.5. Others
6.5.1. Market size and forecast
6.5.2. Market analysis, by country
CHAPTER 7: ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Retail pharmacies
7.2.1. Market size and forecast
7.3. Hospital Pharmacies
7.3.1. Market size and forecast
7.4. Online Retailers
7.4.1. Market size and forecast
7.5. Others
7.5.1. Market size and forecast
CHAPTER 8: ALLERGY TREATMENT MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. North America market size and forecast, by country
8.2.2.1. U.S. market size and forecast, by type
8.2.2.2. U.S. market size and forecast, by treatment
8.2.2.3. U.S. market size and forecast, by dosage form
8.2.2.4. U.S. market size and forecast, by distribution channel
8.2.2.5. Canada market size and forecast, by type
8.2.2.6. Canada market size and forecast, by treatment
8.2.2.7. Canada market size and forecast, by dosage form
8.2.2.8. Canada market size and forecast, by distribution channel
8.2.2.9. Mexico market size and forecast, by type
8.2.2.10. Mexico market size and forecast, by treatment
8.2.2.11. Mexico market size and forecast, by dosage form
8.2.2.12. Mexico market size and forecast, by distribution channel
8.2.3. North America market size and forecast, by type
8.2.4. North America market size and forecast, by treatment
8.2.5. North America market size and forecast, by dosage form
8.2.6. North America market size and forecast, by distribution channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Europe market size and forecast, by country
8.3.2.1. Germany market size and forecast, by type
8.3.2.2. Germany market size and forecast, by treatment
8.3.2.3. Germany market size and forecast, by dosage form
8.3.2.4. Germany market size and forecast, by distribution channel
8.3.2.5. UK market size and forecast, by type
8.3.2.6. UK market size and forecast, by treatment
8.3.2.7. UK market size and forecast, by dosage form
8.3.2.8. UK market size and forecast, by distribution channel
8.3.2.9. France market size and forecast, by type
8.3.2.10. France market size and forecast, by treatment
8.3.2.12. France market size and forecast, by dosage form
8.3.2.13. France market size and forecast, by distribution channel
8.3.2.14. Rest of Europe market size and forecast, by Type
8.3.2.15. Rest of Europe market size and forecast, by treatment
8.3.2.16. Rest of Europe market size and forecast, by dosage form
8.3.2.17. Rest of Europe market size and forecast, by distribution channel
8.3.3. Europe market size and forecast, by type
8.3.4. Europe market size and forecast, by treatment
8.3.5. Europe market size and forecast, by dosage form
8.3.6. Europe market size and forecast, by distribution channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Asia-Pacific market size and forecast, by country
8.4.2.1. Japan market size and forecast, by type
8.4.2.2. Japan market size and forecast, by treatment
8.4.2.3. Japan market size and forecast, by dosage form
8.4.2.4. Japan market size and forecast, by distribution channel
8.4.2.5. China market size and forecast, by type
8.4.2.6. China market size and forecast, by treatment
8.4.2.7. China market size and forecast, by dosage form
8.4.2.8. China market size and forecast, by distribution channel
8.4.2.9. India market size and forecast, by type
8.4.2.10. India market size and forecast, by treatment
8.4.2.11. India market size and forecast, by dosage form
8.4.2.12. India market size and forecast, by distribution channel
8.4.2.13. Australia market size and forecast, by type
8.4.2.14. Australia market size and forecast, by treatment
8.4.2.15. Australia market size and forecast, by dosage form
8.4.2.16. Australia market size and forecast, by distribution channel
8.4.2.17. Rest of Asia-Pacific market size and forecast, by type
8.4.2.18. Rest of Asia-Pacific market size and forecast, by treatment
8.4.2.19. Rest of Asia-Pacific market size and forecast, by dosage form
8.4.2.20. Rest of Asia-Pacific market size and forecast, by distribution channel
8.4.3. South Korea market size and forecast, by type
8.4.4. South Korea market size and forecast, by treatment
8.4.5. South Korea market size and forecast, by dosage form
8.4.6. South Korea market size and forecast, by distribution channel
8.4.7. Asia-Pacific market size and forecast, by type
8.4.8. Asia-Pacific market size and forecast, by treatment
8.4.9. Asia-Pacific market size and forecast, by dosage form
8.4.10. Asia-Pacific market size and forecast, by distribution channel
8.1. LAMEA
8.1.1. Key market trends and opportunities
8.1.2. Asia-Pacific market size and forecast, by country
8.1.2.1. Brazil market size and forecast, by type
8.1.2.2. Brazil market size and forecast, by treatment
8.1.2.3. Brazil market size and forecast, by dosage form
8.1.2.4. Brazil market size and forecast, by distribution channel
8.1.2.5. South Africa market size and forecast, by type
8.1.2.6. South Africa market size and forecast, by treatment
8.1.2.7. South Africa market size and forecast, by dosage form
8.1.2.8. South Africa market size and forecast, by distribution channel
8.1.2.9. Saudi Arabia market size and forecast, by type
8.1.2.10. Saudi Arabia market size and forecast, by treatment
8.1.2.11. Saudi Arabia market size and forecast, by dosage form
8.1.2.12. Saudi Arabia market size and forecast, by distribution channel
8.1.2.13. Turkey market size and forecast, by type
8.1.2.14. Turkey market size and forecast, by treatment
8.1.2.15. Turkey market size and forecast, by dosage form
8.1.2.16. Turkey market size and forecast, by distribution channel
8.1.2.17. Rest of LAMEA market size and forecast, by type
8.1.2.18. Rest of LAMEA market size and forecast, by treatment
8.1.2.19. Rest of LAMEA market size and forecast, by dosage form
8.1.2.20. Rest of LAMEA market size and forecast, by distribution channel
8.1.2.21. LAMEA market size and forecast, by type
8.1.2.22. LAMEA market size and forecast, by treatment
8.1.2.23. LAMEA market size and forecast, by dosage form
8.1.2.24. LAMEA market size and forecast, by distribution channel
CHAPTER 9: COMPANY PROFILES
9.1. Merck KGaA (Allergopharma)
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments
9.2. GlaxoSmithKline plc
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.3. F. Hoffmann-La Roche Ltd. (Genentech Inc.)
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. Johnson & Johnson
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. Allergy Therapeutics plc
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. AALK-Abello A/S
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. Sanofi SA
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments
9.8. Stallergenes Greer plc
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Allergan Plc.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.10. Merck & Co. Inc.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
